80%Confidence
0Views
FDASource
2026-04-20Date
Summary
Teva's recall due to CGMP deviations and use of unapproved materials reveals serious compliance failures in its supply chain. This could lead to FDA enforcement actions and damage its credibility in the generic drug market.
Actionable: Assess Teva's regulatory risk profile and monitor for any further quality-related announcements.
AI Confidence: 80%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionWithin U.S
productClonidine Transdermal System, USP, 0.2 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Covers, Rx only, Manufactured by: Actavis Laboratories
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now